View Financial HealthSartorius 배당 및 자사주 매입배당 기준 점검 0/6Sartorius 은(는) 현재 수익률이 0.32% 인 배당금 지급 회사입니다.핵심 정보0.3%배당 수익률-0.004%자사주 매입 수익률총 주주 수익률0.3%미래 배당 수익률0.4%배당 성장률9.6%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향33%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.2% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).Buy Or Sell Opportunity • Mar 02Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to €234. The fair value is estimated to be €294, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (91% net debt to equity). Share price has been volatile over the past 3 months (5.2% average weekly change).New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.Buy Or Sell Opportunity • Feb 09Now 21% undervaluedOver the last 90 days, the stock has risen 1.2% to €235. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Buy Or Sell Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €227. The fair value is estimated to be €285, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 1SRT3 Italian 시장에서 주목할만한 배당금을 지급하지 않으므로 지급이 안정적인지 확인할 필요가 없습니다.배당금 증가: 1SRT3 Italian 시장에서 주목할만한 배당금을 지급하지 않으므로 지급액이 증가하는지 확인할 필요가 없습니다.배당 수익률 vs 시장Sartorius 배당 수익률 vs 시장1SRT3의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1SRT3)0.3%시장 하위 25% (IT)1.7%시장 상위 25% (IT)4.5%업계 평균 (Life Sciences)0.8%분석가 예측 (1SRT3) (최대 3년)0.4%주목할만한 배당금: 1SRT3 의 배당금( 0.32% )은 Italian 시장에서 배당금 지급자의 하위 25%( 1.65% )와 비교해 주목할 만하지 않습니다.고배당: 1SRT3 의 배당금( 0.32% )은 Italian 시장에서 배당금 지급자의 상위 25%( 4.52% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 1SRT3 Italian 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 1SRT3 Italian 시장에서 주목할만한 배당금을 지급하지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 04:31종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sartorius Aktiengesellschaft는 38명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35명의 분석가 더 보기
Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).
Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
Buy Or Sell Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.2% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Italian dividend payers (5.0%). Lower than average of industry peers (0.9%).
Buy Or Sell Opportunity • Mar 02Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to €234. The fair value is estimated to be €294, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (91% net debt to equity). Share price has been volatile over the past 3 months (5.2% average weekly change).
New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Feb 09Now 21% undervaluedOver the last 90 days, the stock has risen 1.2% to €235. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.
공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).
공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
Buy Or Sell Opportunity • May 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €227. The fair value is estimated to be €285, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.